Rospo, Giuseppe
Chilà, Rosaria
Matafora, Vittoria
Basso, Veronica
Lamba, Simona
Bartolini, Alice
Bachi, Angela
Di Nicolantonio, Federica
Mondino, Anna
Germano, Giovanni
Bardelli, Alberto http://orcid.org/0000-0003-1647-5070
Funding for this research was provided by:
Fondazione AIRC under 5 per Mille 2018 (ID. 21091 program)
AIRC MFAG 2020 (Grant-ID 24604)
AIRC under IG 2018 (ID. 21923 project)
International Accelerator Award, ACRCelerate (Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB), and AIRC (22795))
European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no.101020342)
IMI PERSIST-SEQ (contract n. 101007937)
AIRC under IG 2018 (21763)
AIRC 5x1000 (22737)
Article History
Received: 14 September 2022
Accepted: 12 December 2023
First Online: 19 January 2024
Declarations
:
: All animal procedures were approved by the Ethical Commission of the Istituto Fondazione di Oncologia Molecolare ETS (IFOM ETS), the University of Turin and by the Italian Ministry of Health and were performed in accordance with institutional guidelines (4D.L.N.116, G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council Directive 86/609, OJ L 358, 1, 12-12-1987; NIH Guide for the Care and Use of Laboratory Animals, US National Research Council, 1996). The number of mice included in the experiments and the inclusion/exclusion criteria were based on institutional guidelines (above). Our protocol limited us to use six- to eight-weeks old female male BALB/c and NOD-SCID. Mice were obtained from Charles River (Calco, Como Italy).
: Not applicable.
: A. Bardelli served in a consulting/advisory role for Illumina and Inivata. A. Bardelli and G.G. are cofounders and shareholders of NeoPhore. A. Bardelli is a member of the NeoPhore scientific advisory board. The remaining authors declare that they do not have any competing interests.